The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Hun | - |
dc.contributor.author | Lee, Kiyoung | - |
dc.contributor.author | Park, Ie Byung | - |
dc.contributor.author | Choi, Cheol Soo | - |
dc.contributor.author | Ahn, Tae Hoon | - |
dc.contributor.author | Lee, Dae Ho | - |
dc.date.available | 2020-03-03T07:47:53Z | - |
dc.date.created | 2020-02-24 | - |
dc.date.issued | 2019-10 | - |
dc.identifier.issn | 0168-8227 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/18109 | - |
dc.description.abstract | Aims: Dipeptidyl peptidase 4 inhibitors (DPP4Is) can increase sympathetic activity. We aimed to evaluate the direct association between serum DPP4 activity and sympathetic activity in humans. Methods: Fasting serum DPP4 activity and plasma levels of catecholamines and their metabolites were measured in 211 patients with type 2 diabetes mellitus (T2DM) treated with DPP4I (n = 146) or non-DPP4I therapy (n = 65) and in healthy control subjects (n = 30). Results: Although there were no differences in plasma levels of catecholamines and their metabolites between the DPP4I and non-DPP4I groups, the levels in both of these groups were lower than those in the healthy control group. In DPP4I-treated patients, serum DPP4 activity showed an inverse correlation with plasma levels of norepinephrine (NE) (r = -0.339, p < 0.01), metanephrine (MET) (r = -0.251, p < 0.01) and normetanephrine (r = -0.312, p < 0.001). In addition, plasma MET level showed a weak inverse correlation with serum DPP4 activity in the combined T2DM group. In DPP4I-treated patients, the inverse correlation between DPP4 activity and plasma NE remained significant even after multiple adjustments. Conclusions: Our results suggest that although sympathetic activity is lower in patients with T2DM, the greater the suppression of DPP4 activity by DPP4I therapy, the greater the increase in sympathetic activity is, which may have clinical implications in high risk T2DM patients. (C) 2019 Elsevier B.V. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.relation.isPartOf | DIABETES RESEARCH AND CLINICAL PRACTICE | - |
dc.subject | ANGIOTENSIN-CONVERTING ENZYME | - |
dc.subject | DIPEPTIDYL PEPTIDASE-4 | - |
dc.subject | BLOOD-PRESSURE | - |
dc.subject | IV INHIBITION | - |
dc.subject | HEART-RATE | - |
dc.subject | METANEPHRINE | - |
dc.subject | VILDAGLIPTIN | - |
dc.subject | SYSTEM | - |
dc.title | The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000500225500018 | - |
dc.identifier.doi | 10.1016/j.diabres.2019.107832 | - |
dc.identifier.bibliographicCitation | DIABETES RESEARCH AND CLINICAL PRACTICE, v.156 | - |
dc.identifier.scopusid | 2-s2.0-85072034884 | - |
dc.citation.title | DIABETES RESEARCH AND CLINICAL PRACTICE | - |
dc.citation.volume | 156 | - |
dc.contributor.affiliatedAuthor | Kim, Tae Hun | - |
dc.contributor.affiliatedAuthor | Lee, Kiyoung | - |
dc.contributor.affiliatedAuthor | Park, Ie Byung | - |
dc.contributor.affiliatedAuthor | Choi, Cheol Soo | - |
dc.contributor.affiliatedAuthor | Ahn, Tae Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Dae Ho | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Dipeptidyl peptidase 4 | - |
dc.subject.keywordAuthor | Catecholamines | - |
dc.subject.keywordAuthor | Sympathetic nervous system | - |
dc.subject.keywordAuthor | Dipeptidyl peptidase 4 inhibitors | - |
dc.subject.keywordAuthor | Type 2 diabetes mellitus | - |
dc.subject.keywordPlus | ANGIOTENSIN-CONVERTING ENZYME | - |
dc.subject.keywordPlus | DIPEPTIDYL PEPTIDASE-4 | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | IV INHIBITION | - |
dc.subject.keywordPlus | HEART-RATE | - |
dc.subject.keywordPlus | METANEPHRINE | - |
dc.subject.keywordPlus | VILDAGLIPTIN | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.